Novo Nordisk nominates three new board directors, two with pharma experience
Source: SeekingAlpha
2026-02-20 09:24:40 ET
More on Novo Nordisk
- Novo Nordisk Is Under Pressure - And Trading At A Discount
- Novo Nordisk: The Possible Upside
- Novo Nordisk: How Low Is Too Low? (Downgrade, Technical Analysis)
- Novo Nordisk board proposes DKK 7.95 final dividend for 2025, initiates DKK 15B buyback
- Novo Nordisk’s 2026 outlook in focus as competition pressures sales
Read the full article on Seeking Alpha
For further details see:
Novo Nordisk nominates three new board directors, two with pharma experience
Takeda Pharmaceutical Company Limited American Depositary Shares
NASDAQ: TAK
TAK Trading
-0.63% G/L:
$18.115 Last:
1,281,262 Volume:
$18.15 Open:
TAK Latest News
March 02, 2026 02:00:00 am
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
February 24, 2026 09:35:00 am
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
TAK Stock Data
$57,107,745,653
3,115,826,299
N/A
157
N/A
Pharmaceuticals
Healthcare
JP
Chuo-ku
